Cover Image
Market Research Report

AI in Drug Development & Clinical Trials - World - 2020

Published by Signify Research Product code 949933
Published Content info
Delivery time: 1-2 business days
Price
Back to Top
AI in Drug Development & Clinical Trials - World - 2020
Published: will be released November 30, 2020 Content info:
Description

Report Overview

Market

  • Identify the products and end-markets driving growth
  • Review the market drivers and barriers for growth
  • Quantitative analysis of market size and forecast growth

Technology

  • Market analysis for AI applications in information and disease models, drug design & optimisation, preclinical & clinical trials
  • Impact of advanced machine learning and deep learning
  • Influence of next generation DNA sequencing and processing technologies

Competition

  • Market share estimates for the leading vendors
  • Detailed profiles of selected vendors, with SWOT analysis for each
  • Identify potential partners and acquisition targets

Strategy

  • Review go-to-market strategies
  • Analysis and insights to support your strategy and business planning
  • Product pricing and software delivery strategies

Report Features:

  • Expert commentary on the market Trends
  • Primary research method ensures accuracy and reliability
  • Direct access to the lead Analyst
  • Highly data-centric, with numerous segmentations of the market
  • Detailed analysis by product, sales model and application to highlight growth opportunities
  • Robust forecasts driven by proprietary database of hospital infrastructure
  • Report focused on global market coverage with detailed country analysis
  • Actionable, jargon-free analyst insight and opinion

Key issues Addressed:

  • How large is the global market for AI in drug development in terms of revenue and how will this change over the next five years?
  • How does the market break out in terms of applications for information synthesis, drug design and clinical trials?
  • How does the market break out in terms of clinical areas (oncology, neurology, infectious disease, other)?
  • How is the market split between licencing models?
  • What are the main drivers behind each market segment?
  • Who are the leading vendors and what is needed to stay competitive?
Table of Contents

Table of Contents

Chapter 1: Introduction, Scope & Methodology

  • 1.1. Who We Are
  • 1.2. Research methodology
  • 1.3. Areas of Expertise
  • 1.4. The Next Step
  • 1.5. Scope for AI in Drug Development
  • 1.6. Information & Disease Models Defined
  • 1.7. Drug Design & Optimisation Defined
  • 1.8. Preclinical & Clinical Trials Defined
  • 1.9. End to End Solutions Defined
  • 1.10. Allied Companies Defined

Chapter 2: Worldwide Market

  • 2.1. The Market Today
  • 2.2. AI in Drug Development: The Use Case
  • 2.3. Investment & Partnerships for AI in DD & CT
  • 2.4. Where is the Money & Growth Growth Forecast?
  • 2.5. ‘Big’ Pharma, Big Tech & Allied Company Impact
  • 2.6. Other Emerging Technologies

Chapter 3: Information & Disease Models

  • 3.1. Introduction
  • 3.2. Drivers and Barriers
  • 3.3. Business Models & Major Product Nuances
  • 3.4. Applications
  • 3.5. Regional Growth
  • 3.6. Chapter Summary

Chapter 4: Drug Design & Optimisation

  • 4.1. Introduction
  • 4.2. Drivers and Barriers
  • 4.3. Business Models & Major Product Nuances
  • 4.4. Applications
  • 4.5. Regional Growth
  • 4.6. End to End Solutions
  • 4.7. End to End Solutions Outlook
  • 4.8. Chapter Summary

Chapter 5: Preclinical & Clinical Trials

  • 5.1. Introduction
  • 5.2. Drivers and Barriers
  • 5.3. Business Models & Major Product Nuances
  • 5.4. Applications
  • 5.5. Regional Growth
  • 5.6. Digital Pathology AI in Drug Development
  • 5.7. Digital Pathology AI Market Outlook
  • 5.8. Chapter Summary

Chapter 6: Competitive Environment

  • 6.1. Company Profiles
    • 6.1.1. Aetion
    • 6.1.2. Atomwise
    • 6.1.3. BenchSci
    • 6.1.4. BenevolentAI
    • 6.1.5. Biofourmise
    • 6.1.6. BioZ
    • 6.1.7. Cyclica
    • 6.1.8. Deep6AI
    • 6.1.9. Exscientia
    • 6.1.10. Glympse Bio
    • 6.1.11. IBM
    • 6.1.12. Innoplexus
    • 6.1.13. Insilico Medicine
    • 6.1.14. Insitro
    • 6.1.15. Inteliquet
    • 6.1.16. Molecular Health
    • 6.1.17. Nuritas
    • 6.1.18. Owkin
    • 6.1.19. PEACCEL
    • 6.1.20. Perspectum
    • 6.1.21. Recursion Pharmaceuticals
    • 6.1.22. Relay Therapeutics
    • 6.1.23. Schrödinger
    • 6.1.24. Sensyne Health
    • 6.1.25. Sophia Genetics
    • 6.1.26. Tempus
    • 6.1.27. TriNetX
    • 6.1.28. XtalPi
  • 6.2. Product Maturity Lifecycle
  • 6.3. AI-Pharmaceutical Announced Partnerships

Chapter 7: Concluding Remarks

  • 7.1. Short Term Market Evolution
  • 7.2. Long Term Market Evolution

Appendix

Geographic Definitions

Report Definitions

Back to Top